Andere talen BioArctic AB

Aandelen

BIOA B

SE0010323311

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:39 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
195,5 ^SEK	+3,77%		-0,76%	-27,00%

01/04	BioArctic, Eisai proberen goedkeuring van Amerikaanse FDA te krijgen voor onderhoudsdosis van medicijn tegen de ziekte van Alzheimer	MT
22/03	BioArctic signaleert vertraging in evaluatie door EU-gezondheidsregulator van geneesmiddel voor de ziekte van Alzheimer	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	24/04
Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	22/04
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	20/04
Notice of Annual General Meeting in BioArctic AB (publ)	19/04
BioArctic publishes the Annual Report for 2023	18/04
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB	16/04
Nordic Shares Moved Upward Monday; Invisio Led Increases	15/04
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	12/04
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm	10/04
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01/04
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01/04
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25/03
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit	22/03
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22/03
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	22/03
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease	19/03
New data on lecanemab presented at the 2024 AD/PD™ congress	11/03
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	11/03
BioArctic's partner Eisai presents updated sales simulation for Leqembi at its annual press conference	08/03
BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference	07/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioArctic AB

Aandelen

BIOA B

SE0010323311

Andere talen

Filters